Melanoma is a very serious and increasingly prevalent skin cancer. More than 100,000 new cases are diagnosed in the U.S. each year and the incidence of this cancer is increasing by about 10% annually. Melanoma is the fifth most common cancer in men and the sixth most common cancer in women, causing over 7,500 deaths in the U.S. each year. The Wistar technology represents a novel therapeutic approach for this lethal disease.

PCT Application No. PCT/US2006/25324 (WO 2007/002811, published 01/4/2007); a U.S. application has been filed.

This technology is available for exclusive license to a company developing vaccines against melanoma. Sponsored research to further develop the technology will also be considered.

Somasundaram et al. (2006) Human Leokocyte Antigen-A2-Restricted CTL Responses to Mutated BRAF Peptides in Melanoma Patients, Cancer Research Vol. 66 No. 6, 3287-3293